
Boost in yields: x5 in CHO x7 in HEK
Introducing C3P3® technology
Biomedicines consist of recombinant proteins, produced by cells in culture. Current manufacturing technologies rely on the mRNA synthesis by the host cell, such mRNA being then decoded by ribosomes to produce the proteins of interest.
However, the host cell’s limited mRNA synthesis capacity significantly constrains the efficiency of this production process.
Eukarÿs’ C3P3® technology is the first to overcome this bottleneck. Operating alongside the host cell’s mRNA synthesis machinery, it enables the production of high amounts of mRNA-of-interest.
C3P3® is based on an engineered enzyme, developed entirely by synthetic biology, that creates a second mRNA synthesis and maturation pathway in the host cell, resulting in a significant increase in the production yield of biomedicines.

A first-in-a-kind technology
mRNA is a very complex molecule
The eukaryotic mRNA synthesis process relies on:
- RNA polymerase II complex of 12 subunits,
- 1.000+ transcription factors,
- Hundreds of post-transcriptional factors for the mRNA post-transcriptional maturation and homeostasis.
C3P3® technology is the first ever to perform both:
mRNA synthesis at high yields
Post-transcriptional modifications of mRNA, which are essential for its translation (capping, polyadenylation…)
High-performances
Universal
C3P3® technology can be used to produce any type of protein or multi-protein complex, whether secreted or intracellular.
C3P3® can therefore be adapted to virtually all biological products:
– Monoclonal antibodies and related proteins
– Other recombinant proteins
– Virus-like particles
– Wild-type RNA viruses
– Recombinant RNA viruses
– …
Preserving on biomedicines’ quality
C3P3® technology has no effect on the functional activity of proteins, in particular post-translational modifications.
Wild-type folding. Unchanged glycosylation.
No spurious transcription
The C3P3® enzyme binds to a specific promoter, and therefore does not induce spurious transcription of the host-cell genome.
No cytotoxicity specifically induced by the C3P3® enzyme has been observed.
C3P3® for stable expression
Transcription is made in the nucleus

C3P3 enzyme synthesis by cellular machinery
mRNA-of-Interest synthesis and maturation by the C3P3 enzyme
Protein-of-Interest synthesis by the cellular machinery
C3P3® for transient expression
Transcription is made in the cytoplasm

C3P3 enzyme synthesis by cellular machinery
Protein-of-Interest synthesis by the cellular machinery
Scientific publications
C3P3-G1: first generation of a eukaryotic artificial cytoplasmic expression system
Jais, P. H., E. Decroly, E. Jacquet, M. Le Boulch, A. Jais, O. Jean-Jean, H. Eaton, P. Ponien, F. Verdier, B. Canard, S. Goncalves, S. Chiron, M. Le Gall, P. Mayeux and M. Shmulevitz (2019). « C3P3-G1: first generation of a eukaryotic artificial cytoplasmic expression system. » Nucleic Acids Res 47(5): 2681-2698.
Rational design of an artificial tethered enzyme for non-templated post-transcriptional mRNA polyadenylation by the second generation of the C3P3® system
Le Boulch, M., E. Jacquet, N. Nhiri, M. Shmulevitz and P. H. Jais (2023). « Rational design of an artificial tethered enzyme for non-templated post-transcriptional mRNA polyadenylation by the second generation of the C3P3® system. » Scientific reports 14: 5156
CRISPR/Cas9 screens identify key host factors that enhance rotavirus reverse genetics efficacy and vaccine production
Y. Zhu, M.E. Sullender, D.E. Campbell, L. Wang, S. Lee, T. Kawagishi, G. Hou, A. Dizdarevic, P.H. Jais, M.T. Baldridge, S. Ding (2024). « CRISPR/Cas9 screens identify key host factors that enhance rotavirus reverse genetics ef cacy and vaccine production.”, Vaccines
African Swine Fever Virus NP868R Capping Enzyme Promotes Reovirus Rescue during Reverse Genetics by Promoting Reovirus Protein Expression, Virion Assembly, and RNA Incorporation into Infectious Virions
Eaton, H. E., T. Kobayashi, T. S. Dermody, R. N. Johnston, P. H. Jais and M. Shmulevitz (2017). « African Swine Fever Virus NP868R Capping Enzyme Promotes Reovirus Rescue during Reverse Genetics by Promoting Reovirus Protein Expression, Virion Assembly, and RNA Incorporation into Infectious Virions. » J Virol 91(11): JVI.02416-02416.
Mucosal and systemic neutralizing antibodies to norovirus induced in infant mice orally inoculated with recombinant rotaviruses
Kawagishi, T., L. Sanchez-Tacuba, N. Feng, V. P. Costantini, M. Tan, X. Jiang, K. Y. Green, J. Vinje, S. Ding and H. B. Greenberg (2023). « Mucosal and systemic neutralizing antibodies to norovirus induced in infant mice orally inoculated with recombinant rotaviruses. » Proc Natl Acad Sci U S A 120(9): e2214421120.
SEMPER: Stoichiometric expression of mRNA polycistrons by eukaryotic ribosomes for compact, ratio-tunable multi-gene expression
Qin, C., Y. Xiang, J. Liu, R. Zhang, Z. Liu, T. Li, Z. Sun, X. Ouyang, Y. Zong, H. M. Zhang, Q. Ouyang, L. Qian and C. Lou (2023). « Precise programming of multigene expression stoichiometry in mammalian cells by a modular and programmable transcriptional system. » Nat Commun 14(1): 1500.
An Optimized Reverse Genetics System Suitable for Efficient Recovery of Simian, Human, and Murine-Like Rotaviruses
Sanchez-Tacuba, L., N. Feng, N. J. Meade, K. H. Mellits, P. H. Jais, L. L. Yasukawa, T. K. Resch, B. Jiang, S. Lopez, S. Ding and H. B. Greenberg (2020). « An Optimized Reverse Genetics System Suitable for Efficient Recovery of Simian, Human, and Murine-Like Rotaviruses. » J Virol 94(18): e01294-01220.
Direct Interaction of Coronavirus Nonstructural Protein 3 with Melanoma Differentiation-Associated Gene 5 Modulates Type I Interferon Response during Coronavirus Infection
Sun, X., L. Quan, R. Chen and D. Liu (2022). « Direct Interaction of Coronavirus Nonstructural Protein 3 with Melanoma Differentiation-Associated Gene 5 Modulates Type I Interferon Response during Coronavirus Infection. » Int J Mol Sci 23(19): 11692
Want to try our technology?
Step 1:
An exploratory call to understand your needs.
Step 2:
Validate the technology with a proof of concept on the molecules of your choice.
Step 3:
Full deployment across your biomedicines, ensuring higher yields and lower costs.
Trusted by:
